Duration of hemolysis among infants with hemolytic disease of the fetus and newborn

Timothy M. Bahr,Kenneth J. Moise,Kathy Lowry,Martha A. Monson,Ibrahim A. Hammad,Sasidhar Goteti,Sarah J. Ilstrup,Paul Vanasco,Robin K. Ohls,Robert D. Christensen

DOI: https://doi.org/10.1038/s41372-024-02163-3

2024-11-19

Journal of Perinatology

Abstract:Among infants with hemolytic disease of the fetus and newborn (HDFN) little data exist on the lifespan of their passively acquired red blood cell (RBC) alloantibodies [1, 2]. Herein we assessed this issue in a pilot study where infants with HDFN had their hemolytic rate measured serially using end-tidal breath carbon monoxide (ETCOc) [3]. Additionally, we collected information on the pathogenesis of the "late anemia," commonly occurring when these infants are several weeks old, and frequently necessitating late RBC transfusions [1, 4, 5]. ETCOc measurements were made using the FDA-approved CoSense monitor (Capnia Inc. Foster City, CA). The device quantifies carbon monoxide (CO) in exhaled breath corrected for ambient CO. If a neonate has hemolysis, the ETCOc will be >95th percentile upper reference for healthy neonates (>1.7 ppm) [3].

pediatrics,obstetrics & gynecology